



# Did you know?

## What prostate cancer looks like today

Prostate cancer is the **fourth most commonly diagnosed cancer** worldwide<sup>1</sup>



Standard TRUS prostate biopsies are often imprecise, with the ability to detect only



**30-41%** of cancers<sup>2</sup>

MRI-targeted biopsies have been shown to improve diagnosis of **high-risk cancers by 30%**<sup>3</sup>



Reducing unnecessary biopsies can enhance the **patient** experience by reducing post-procedure complications<sup>4</sup>



Due to inaccurate risk profiling

Up to **40%** of aggressive prostate cancers are **undertreated**<sup>5</sup>

Up to **50%** of insignificant prostate cancers are **overtreated**<sup>6</sup>



Research suggests that **prostate cancer is most prevalent** in men of African descent, compared to men of European or Asian descent<sup>7</sup>



Philips solutions for prostate diagnosis are in use at **22 of the 25 top-ranked** US cancer hospitals<sup>8</sup>



Discover how Philips can help support your prostate cancer program: [www.philips.com/prostatesolutions](http://www.philips.com/prostatesolutions)

1. Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249. <https://doi.org/10.3322/caac.21660>

2. Choi YH, et al. Comparison of cancer detection rates between TRUS-guided biopsy and MRI-targeted biopsy according to PSA level in biopsy-naïve patients: a propensity score matching analysis. Clin Genitourin Cancer. 2019 Feb;17(1):e19-e25. doi: 10.1016/j.clgc.2018.09.007. Epub 2018 Sep 13. PMID: 30415878.

3. Siddiqui MM, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390-397.

4. Yarlagadda VK, et al. MRI/US fusion-guided prostate biopsy allows for equivalent cancer detection

with significantly fewer needle cores in biopsy-naïve men. Diagn Interv Radiol. 2018 May-Jun;24(3):115-120. doi: 10.5152/dir.2018.17422. PMID: 29770762; PMCID: PMC5951198.

5. Sonn GA, et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol. 2013 Jan;189(1):86-91. doi: 10.1016/j.juro.2012.08.095. Epub 2012 Nov 14. PMID: 23158413; PMCID: PMC3561472.

6. Loeb S, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062.

7. Rebbeck TR, et al. Temporal trends and racial disparities in global prostate cancer prevalence. Can J Urol. 2014 Oct;21(5):7496-506. PMID: 25347377; PMCID: PMC4955669.

8. U.S. News and World Report: 2017 Best Hospitals Ranking (Cancer)